OncLive TV

Sumanta Kumar Pal, MD, FASCO, discusses data supporting KIM-1 as a potential biomarker to inform adjuvant immunotherapy use in high-risk resected RCC.

Linda R. Duska, MD, MPH, discusses the background of the phase 3 KEYNOTE-A18 trial of pembrolizumab plus chemoradiotherapy in cervical cancer.

Alicia Morgans, MD, MPH, discusses enzalutamide plus radium-223 in with metastatic castration-resistant prostate cancer.

Timothy R. Gershon, MD, PhD, discusses ongoing research priorities neurofibromatosis type 1–associated plexiform neurofibromas

Paolo Ghia, MD, highlights the rationale for evaluating pirtobrutinib for the treatment of patients with relapsed/refractory CLL.

Eileen M. O’Reilly, MD, discusses the potential of tumor treating fields for the treatment of patients with locally advanced pancreatic cancer.

Jens Bedke, MD, discusses findings from subgroup analyses of the phase 3 EV-302/KEYNOTE-A39 trial in untreated metastatic urothelial cancer.

Narjust Florez, MD, discusses emerging strategies to address immune checkpoint inhibitor resistance in non–small cell lung cancer.

Narjust Florez, MD, discusses current treatment preferences in frontline IO for BRAF V600E–mutated metastatic non–small cell lung cancer.

Marina Kremyanskaya, MD, PhD, discusses safety and early efficacy findings with divesiran in polycythemia vera.

Martin Dietrich, MD, PhD, discusses the FDA accelerated approval of zongertinib for HER2-mutated or metastatic nonsquamous NSCLC.

Rachel E. Sanborn, MD, discusses preclinical and early clinical data supporting the use of the IB6-directed ADC sigvotatug vedotin in patients with NSCLC.

Narjust Florez, MD, discusses treatment preferences in borderline resectable NSCLC, based on real-time polling conducted during the Bridging the Gaps in Lung Cancer 2025 meeting.

Aaron C. Logan, MD, PhD, discusses the FDA approval of the obe-cel in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Narjust Florez, MD, discusses current treatment preferences in SCLC, based on real-time polling conducted during the Bridging the Gaps in Lung Cancer 2025 meeting.

Narjust Florez, MD, discusses current treatment preferences in SCLC, based on real-time polling conducted during the 2025 Bridging the Gaps in Lung Cancer meeting.

Jyoti Malhotra, MD, MPH, discusses future research directions for sigvotatug vedotin in non–small cell lung cancer.

Janice Mehnert, MD, discusses the rationale for incorporating IL-6 receptor blockade into a combination with checkpoint inhibition for patients with advanced melanoma.

Cathy Eng, MD, FACP, FASCO, discusses efforts to shift emerging targeted therapies into earlier treatment lines for patients with mCRC.

Timothy F. Cloughesy, MD, discusses the FDA approval of dordaviprone for the treatment of patients with H3K27M-mutated diffuse midline glioma.

Rocío García-Carbonero, MD, outlines diagnostic and molecular considerations for poorly differentiated GI neuroendocrine carcinoma.

Alexander B. Olawaiye, MD, discusses future research directions with relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, discusses data with the trispecific antibody JNJ-5322 in relapsed/refractory multiple myeloma.

Tina Cascone, MD, PhD, discusses of perioperative nivolumab vs placebo in patients with resectable non–small cell lung cancer.

Kathleen A. Dorritie, MD, discusses the role of quadruplet regimens for the treatment of patients with multiple myeloma.

Evelyn Y.T. Wong, MD, discusses survival outcomes and molecular characteristics of patients with early-onset colorectal cancer from a cohort in Singapore.

Masatoshi Kudo, MD, PhD, discusses a MAIC evaluating nivolumab/ipilimumab vs durvalumab/tremelimumab and atezolizumab/bevacizumab for unresectable HCC.

Naomi B. Haas, MD, discusses previously conducted trials that supported the initiation of the KEYNOTE-564 trial of adjuvant pembrolizumab in RCC.

Suzanne George, MD, discusses the evolving development of targeted therapies for patients with gastrointestinal stromal tumor.

Rana R. McKay, MD, FASCO, details the significance of casdatifan plus cabozantinib demonstrating better responses vs the respective agents alone in ccRCC.